Effect of Wound infiltration of sole Levobupivacaine versus Combined Ketorolac and Levobupivacaine on postoperative pain after cesarean section : a Randomized Double-blinded Controlled Trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180626001

Enrollment

160

Registered

2018-06-26

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

levobupivacaine 50 mg local infiltration around surgical cesarean section wound before skin closure in woman undergo spinal analgesia,Ketorolac 30 mg and levobupivacaine 50 mg local infiltration aroun

Active Comparator Drug,Experimental Drug,Active Comparator Drug,Experimental Drug

SB&#45

sole levobupivacaine,SB&#45

combined ketorolac and levobupivacaine,GA&#45

sole levobupivacaine,GA&#45

combined ketorolac and levobupivacaine

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: -pregnant woman at age of 18-40 years old -cesarean section

Exclusion criteria

Exclusion criteria: 1 cardiovascular disease 2 liver disease,renal disease 3 hypovolemic shock 4 drug allergy 5 active peptic ulcer 6 BMI >30 kg/m2 7 intervention refusal

Design outcomes

Primary

Measure	Time frame
pain score 24 hours after end of the intervention visual analog scale	—

Secondary

Measure	Time frame
number of intravenous analgesic drug after intervention 24 hours after end of the intervention medical record	—

Countries

Thailand

Contacts

Public ContactRugruedee Wongsree

Thammasat university hospital

woftzang@gmail.com+66868772735

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Effect of Wound infiltration of sole Levobupivacaine versus Combined Ketorolac and Levobupivacaine on postoperative pain after cesarean section : a Randomized Double&#45;blinded Controlled Trial.